![]() | |
Company type | Public |
---|---|
SEHK: 853 | |
Industry | Medical Devices |
Founded | 1998 |
Headquarters | Shanghai, China |
Key people | Zhaohua Chang, CEO Martin Sun, CFO Qiyi Luo, CTO |
Revenue | ![]() |
![]() | |
![]() | |
Number of employees | 9000 (2022) |
Website | www |
MicroPort is a multinational medical technology developer and manufacturer that is primarily headquartered in Shanghai, China. It mainly designs and produces medical devices for a range of fields including cardiology, interventional radiology, orthopedics, electrophysiology, and surgical management. [2] MicroPort is considered one of the global Medtech Big 100 and has been consistently known as the leading spender in research and development by percentage of revenue. [3] [4]
MicroPort was founded in 1998 by Zhaohua Chang, who currently serves as CEO, chairman, and Director. [5] The company rose to prominence from the early success of its coronary stent line due its focus on serving the needs of the Chinese device market. [6] [7] It is now one of the top global manufacturers of cardiac interventional devices. [8] Notably, it produces the world's first and only commercially available targeted drug eluting stent system, which uses a significantly reduced amount of drug than traditional drug eluting stents while maintaining effectiveness. [9] [10] [11] [12] As of early 2018, MicroPort is one of few medical device companies still developing a commercial coronary bioresorbable stent with ongoing clinical trials. [13] [14] [15]
Beginning in the 2010s, MicroPort has rapidly expanded around the world via international acquisitions to other medical device industries, including orthopedics and cardiac rhythm management. [16] [17] These acquisitions have been followed up with substantial local investment, including a US$398 Million investment in 2019 to develop pacemakers and defibrillators in France. [18]
In 2022, MicroPort established its US headquarters in Irvine, California with facilities that include a manufacturing base and innovation center. [19] As of 2022, its principal business is valued at over US$6.5 Billion. [20]
In 2014, MicroPort expanded operations in the United States by acquiring Wright Medical's OrthoRecon business to become the 6th largest international producer of orthopedic devices at the time. [21] MicroPort's orthopedic business is based in Arlington, Tennessee and in 2018 has expanded its business into India. [22]
In 2018, MicroPort and LivaNova closed the sale of LivaNova's cardiac rhythm management business for $190M. [17]
In 2018, MicroPort purchased Lombard Medical, a UK-based endovascular device company, from bankruptcy after it defaulted on loans in early 2018. [23]
In 2021, MicroPort purchased Hemovent GmbH, a German-based manufacturer of extracorporeal life support systems. [24]